Worth Seeing!
Explore the Top Performing Stocks in the Nifty 500 Index View list Now View list Now
mw4me logo
Talk to Us | Subscribe | Advisory Services

Top Pharma Companies in India by Market Capitalisation - Identify Top Performing Pharmaceutical Sector Companies for Investment Today

Sensex 73663.72
676.69 (0.93%)

Pharma Sector Overview

Presently, India is the largest provider of generic medicines, occupying a market share of 20 percent with respect to global supply by volume and fulfils nearly 60 percent of global demand for vaccines. Indian pharmaceutical stocks even supply nearly 80 percent of antiretroviral drugs (used in combating AIDS) in the international markets.
There are several benefits of investing in pharma stocks:
  • Long-term profitability – Pharma stocks can be attractive to long-term investors in spite of the volatility. The ever rising industry size and healthcare becoming a critical part of life, investors can make good returns if they invest at the right time.
  • Exponential growth – Being the evolving industry that it is, innovation, scientific breakthroughs, and technological advances can bring in exponential growth for many pharma stocks.
×
×
Filter

Top Pharma Companies in India as on May-2024

|
 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks
Filter
Company Name
Market cap
(Rs. Cr.)
CMP
(Change %)
Latest
P/E
Latest
P/BV
5Y Sales
Gr.(%)
5Y Profit
Gr.(%)
DeciZen
More Info
1
Zydus Lifesciences Ltd.
1,00,367
(Large Cap)
1,008.15
(1.07%)
34.13
5.39
7.68
-0.07
Q V PT
2
Yatharth Hospital & Trauma Care Services Ltd.
3,798
(Small Cap)
437.75
(-1.06%)
58.76
4.65
0.00
0.00
Q V+ PT
3
Wockhardt Ltd.
8,354
(Small Cap)
546.35
(0.32%)
N/A
2.38
-7.60
0.00
Q V PT
4
Vimta Labs Ltd.
1,087
(Small Cap)
498.25
(1.61%)
28.17
3.64
11.43
22.79
Q V+ PT
5
Vijaya Diagnostic Centre Ltd.
8,228
(Small Cap)
784.90
(-2.21%)
67.72
12.24
0.00
0.00
Q V+ PT
6
Unichem Laboratories Ltd.
3,874
(Small Cap)
544.05
(-1.12%)
N/A
1.59
9.99
0.00
Q V PT
7
Torrent Pharmaceuticals Ltd.
89,710
(Large Cap)
2,707.40
(2.14%)
61.25
12.8
10.09
20.94
Q V+ PT
8
Thyrocare Technologies Ltd.
3,447
(Small Cap)
653.05
(0.33%)
48.59
6.53
8.13
-7.14
Q V PT
9
Themis Medicare Ltd.
1,872
(Small Cap)
207.40
(1.97%)
76.3
7.05
11.08
34.06
Q V+ PT
10
Tarsons Products Ltd.
2,299
(Small Cap)
439.40
(1.69%)
42.28
3.89
0.00
0.00
Q V PT
11
Syngene International Ltd.
27,101
(Mid Cap)
686.25
(1.93%)
59.22
6.59
17.55
15.81
Q V+ PT
12
Syncom Formulations (India) Ltd.
1,278
(Small Cap)
13.52
(-0.59%)
50.15
4.6
7.21
10.35
Q V+ PT
13
Suven Pharmaceuticals Ltd.
16,520
(Small Cap)
643.25
(-0.88%)
44.3
8.29
0.00
0.00
Q V PT
14
Suven Life Sciences Ltd.
2,198
(Small Cap)
99.25
(-1.54%)
N/A
2.56
-53.54
-163.87
Q V PT
15
Supriya Lifescience Ltd.
3,051
(Small Cap)
377.30
(-0.47%)
25.22
3.88
16.71
67.00
Q V+ PT
16
Sun Pharmaceutical Industries Ltd.
3,66,354
(Large Cap)
1,532.20
(0.35%)
41.39
5.91
10.69
26.54
Q V PT
17
Sun Pharma Advanced Research Company Ltd.
7,037
(Small Cap)
218.60
(0.81%)
N/A
30.57
24.99
0.00
Q V+ PT
18
Strides Pharma Science Ltd.
8,045
(Small Cap)
871.65
(-0.42%)
107.95
2.27
4.76
-151.49
Q V PT
19
Solara Active Pharma Sciences Ltd.
2,348
(Small Cap)
481.20
(-1.63%)
N/A
1.41
22.61
-221.22
Q V PT
20
SMS Pharmaceuticals Ltd.
1,734
(Small Cap)
204.70
(-0.07%)
41.89
3.31
2.34
-48.56
Q V+ PT
21
Sigachi Industries Ltd.
2,177
(Small Cap)
65.94
(-0.57%)
55.78
5.06
23.28
32.58
Q V+ PT
22
Shilpa Medicare Ltd.
5,071
(Small Cap)
522.90
(0.83%)
N/A
2.23
5.89
-183.46
Q V PT
23
Shalby Ltd.
2,938
(Small Cap)
268.05
(-1.47%)
29.18
2.8
13.24
14.33
Q V PT
24
Sequent Scientific Ltd.
2,969
(Small Cap)
116.90
(-1.76%)
N/A
4.55
10.88
-288.40
Q V PT
25
Sastasundar Ventures Ltd.
921
(Small Cap)
292.75
(1.11%)
N/A
3.4
-100.00
-43.78
Q V PT
26
Sanofi India Ltd.
19,263
(Small Cap)
8,541.80
(2.13%)
35.93
18.21
0.57
9.48
Q V+ PT
27
RPG Life Sciences Ltd.
2,406
(Small Cap)
1,494.55
(2.73%)
28.29
6.62
8.32
38.58
Q V+ PT
28
Rainbow Childrens Medicare Ltd.
13,549
(Small Cap)
1,343
(0.61%)
62.1
11.12
22.62
38.74
Q V PT
29
Procter & Gamble Health Ltd.
7,964
(Small Cap)
4,775
(-0.48%)
36.95
9.28
11.99
36.80
Q V PT
30
Poly Medicure Ltd.
16,047
(Small Cap)
1,647.85
(-1.45%)
66.5
11.45
16.00
20.25
Q V+ PT
Prev 1

Want to pick best stocks Undervalued Pharma Stocks for High returns?

Check Now!
Screens:
AlphaCases All-Weather Stocks 5 Star Rated Stocks Best Nifty 50 Stocks Best Nifty Next 50 Stocks Best Nifty 500 Stocks Best SmallCap Stocks Dividend Opp. Stocks Nifty Financial Services Stocks
×
×

Pharma - Today's Top Gainers

Company Name CMP Price Change(%)
Medicamen Biotech
525.506.19%
FDC
473.804.13%
Gufic Biosciences
334.504.09%
Jagsonpal Pharma
337.103.37%
Aarti Pharmalabs
606.403.36%
View More

Pharma - Today's Top Losers

Company Name CMP Price Change(%)
Mankind Pharma
2,092.10-4.50%
Lincoln Pharma
573.45-4.13%
Indoco Remedies
319.85-2.50%
Vijaya Diagnostic
784.90-2.21%
HealthcareGlobal
355-1.88%
View More

News about Top Pharma Companies in India

Themis Medicare informs about investors presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), Themis Medicare has submitted the Investors’ Presentation of the Company, with respect to Business Overview of the Company. Further, a copy of the same is also available on the website of the Company: https://www.themismedicare.com

The above information is a part of company’s filings submitted to BSE.

15 May, 2024

Themis Medicare - Quaterly Results

The Revenue for the quarter ended  March 2024 of Rs. 978.18 millions grew by 22.11 % from Rs. 801.05 millions.Profit after Tax for the quarter ended March 2024 saw a decline of -48.83% from Rs. 60.43 millions to Rs. 30.92  millions.The company reported a degrowth in operating Profit to 104.14 millions from 134.34 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 978.18 801.05 22.11 3817.61 3543.23 7.74 3817.61 3543.23 7.74
Other Income 11.00 29.47 -62.67 47.56 115.05 -58.66 47.56 115.05 -58.66
PBIDT 104.14 134.34 -22.48 562.89 789.67 -28.72 562.89 789.67 -28.72
Interest 21.61 27.08 -20.20 93.76 95.64 -1.97 93.76 95.64 -1.97
PBDT 82.53 107.26 -23.06 469.13 694.03 -32.40 469.13 694.03 -32.40
Depreciation 30.55 27.96 9.26 122.46 104.95 16.68 122.46 104.95 16.68
PBT 51.98 79.30 -34.45 346.67 589.08 -41.15 346.67 589.08 -41.15
TAX 21.06 18.87 11.61 99.20 156.14 -36.47 99.20 156.14 -36.47
Deferred Tax 3.36 3.87 -13.18 7.00 6.14 14.01 7.00 6.14 14.01
PAT 30.92 60.43 -48.83 247.47 432.94 -42.84 247.47 432.94 -42.84
Equity 92.04 92.03 0.01 92.04 92.03 0.01 92.04 92.03 0.01
PBIDTM(%) 10.65 16.77 -36.52 14.74 22.29 -33.84 14.74 22.29 -33.84
14 May, 2024

Thyrocare Technologies informs about outcome of board meeting

In continuation of prior intimation dated May 07, 2024, regarding holding of a meeting of the Board of Directors of the Company, Thyrocare Technologies has informed that the Board has at its meeting held today May 14, 2024, considered and approved the audited financial results (standalone and consolidated) for the quarter and financial year ended on March 31, 2024. Pursuant to Regulation 33(3) of SEBI Listing Regulations, the standalone and consolidated audited financial results for the quarter and financial year ended on March 31, 2024, along with the Audit Reports on said financial results issued by the Statutory Auditors of the Company, are attached as Annexure - A. Further, it has declared that the Statutory Auditors of the Company have issued unmodified opinion on both the standalone and consolidated financial results for the quarter and financial year ended on March 31, 2024. The declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached as Annexure- B. The Board has recommended a final Dividend of Rs 18 per equity share of face value of Rs 10 each for the financial year 2023-24, for approval at the ensuing Annual General Meeting. The meeting commenced at 2.20 pm and concluded at 3.20 pm today. The highlights of the financial performance of the Company are enclosed.

The above information is a part of company’s filings submitted to BSE.
14 May, 2024

Thyrocare Tech. - Quaterly Results

The revenue zoomed 13.15% to Rs. 1412.30 millions for the quarter ended March 2024 as compared to Rs. 1248.20 millions during the corresponding quarter last year.The Profit  for the quarter ended March 2024 of  Rs. 192.30  millions  grew by 93.66% from Rs. 99.30 millions.Operating profit for the quarter ended March 2024 rose to 364.00 millions as compared to 248.40 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1412.30 1248.20 13.15 5240.20 4864.60 7.72 5240.20 4864.60 7.72
Other Income 28.10 20.70 35.75 71.80 53.90 33.21 71.80 53.90 33.21
PBIDT 364.00 248.40 46.54 1410.60 1174.00 20.15 1410.60 1174.00 20.15
Interest 9.40 6.00 56.67 37.30 22.50 65.78 37.30 22.50 65.78
PBDT 354.60 242.40 46.29 1373.30 1151.50 19.26 1373.30 1151.50 19.26
Depreciation 104.10 94.20 10.51 391.10 340.80 14.76 391.10 340.80 14.76
PBT 250.50 148.20 69.03 982.20 810.70 21.15 982.20 810.70 21.15
TAX 58.20 48.90 19.02 270.80 241.00 12.37 270.80 241.00 12.37
Deferred Tax -12.10 -33.20 -63.55 -29.50 -60.70 -51.40 -29.50 -60.70 -51.40
PAT 192.30 99.30 93.66 711.40 569.70 24.87 711.40 569.70 24.87
Equity 529.50 529.30 0.04 529.50 52930.00 -99.00 529.50 52930.00 -99.00
PBIDTM(%) 25.77 19.90 29.51 26.92 24.13 11.54 26.92 24.13 11.54
14 May, 2024

Thyrocare Tech. - Quaterly Results

The revenue for the March 2024 quarter is pegged at Rs. 1412.30 millions, about 13.15% up against Rs. 1248.20 millions recorded during the year-ago period.Net profit surges 93.66% to Rs. 192.30  millions  from Rs. 99.30 millions in the quarter ended March 2024.Operating Profit saw a handsome growth to 364.00 millions from 248.40 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1412.30 1248.20 13.15 5240.20 4864.60 7.72 5240.20 4864.60 7.72
Other Income 28.10 20.70 35.75 71.80 53.90 33.21 71.80 53.90 33.21
PBIDT 364.00 248.40 46.54 1410.60 1174.00 20.15 1410.60 1174.00 20.15
Interest 9.40 6.00 56.67 37.30 22.50 65.78 37.30 22.50 65.78
PBDT 354.60 242.40 46.29 1373.30 1151.50 19.26 1373.30 1151.50 19.26
Depreciation 104.10 94.20 10.51 391.10 340.80 14.76 391.10 340.80 14.76
PBT 250.50 148.20 69.03 982.20 810.70 21.15 982.20 810.70 21.15
TAX 58.20 48.90 19.02 270.80 241.00 12.37 270.80 241.00 12.37
Deferred Tax -12.10 -33.20 -63.55 -29.50 -60.70 -51.40 -29.50 -60.70 -51.40
PAT 192.30 99.30 93.66 711.40 569.70 24.87 711.40 569.70 24.87
Equity 529.50 529.30 0.04 529.50 52930.00 -99.00 529.50 52930.00 -99.00
PBIDTM(%) 25.77 19.90 29.51 26.92 24.13 11.54 26.92 24.13 11.54
14 May, 2024

Sanofi India - Quaterly Results

Revenue showed a marginal decline at Rs. 7324.00 millions. For the quarter ended March 2024, as compared to corresponding quarter of last year.The Net Profit of the company registered a slight decline of -28.26% to Rs. 1366.00  millions from Rs. 1904.00 millions.The company reported a degrowth in operating Profit to 2254.00 millions from 2557.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202312 202212 % Var
Sales 7324.00 7365.00 -0.56 7324.00 7365.00 -0.56 28511.00 27701.00 2.92
Other Income 65.00 258.00 -74.81 65.00 258.00 -74.81 653.00 715.00 -8.67
PBIDT 2254.00 2557.00 -11.85 2254.00 2557.00 -11.85 8693.00 7759.00 12.04
Interest 3.00 3.00 0.00 3.00 3.00 0.00 17.00 17.00 0.00
PBDT 1984.00 2732.00 -27.38 1984.00 2732.00 -27.38 8854.00 9062.00 -2.30
Depreciation 100.00 97.00 3.09 100.00 97.00 3.09 396.00 419.00 -5.49
PBT 1884.00 2635.00 -28.50 1884.00 2635.00 -28.50 8458.00 8643.00 -2.14
TAX 518.00 731.00 -29.14 518.00 731.00 -29.14 2426.00 2437.00 -0.45
Deferred Tax -82.00 -7.00 1071.43 -82.00 -7.00 1071.43 -7.00 -15.00 -53.33
PAT 1366.00 1904.00 -28.26 1366.00 1904.00 -28.26 6032.00 6206.00 -2.80
Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00
PBIDTM(%) 30.78 34.72 -11.36 30.78 34.72 -11.36 30.49 28.01 8.85
13 May, 2024

Track Now: 5 Star Companies, Large Cap Companies, Mid Cap Companies, Small Cap Companies, Nifty Microcap Companies, Top IT Companies, Tax saver funds, Analyze your Equity Funds, Nifty Index Funds

Trending on MoneyWorks4Me: Stock Reasearch Reports, How many stocks to own in portfolio?, Why PE Ratio is important?, How to Choose Good Stocks?, Types of Mutual Funds, Why funds future upside is more useful than past performance?

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2024.
Rank Company Market Capitalization 2024 (INR  crores)
1 Zydus Lifesciences Ltd. 1,00,367 Crore
2 Yatharth Hospital & Trauma Care Services Ltd. 3,798 Crore
3 Wockhardt Ltd. 8,354 Crore
4 Vimta Labs Ltd. 1,087 Crore
5 Vijaya Diagnostic Centre Ltd. 8,228 Crore
6 Unichem Laboratories Ltd. 3,874 Crore
7 Torrent Pharmaceuticals Ltd. 89,710 Crore
8 Thyrocare Technologies Ltd. 3,447 Crore
9 Themis Medicare Ltd. 1,872 Crore
10 Tarsons Products Ltd. 2,299 Crore
Find best pharma stocks to buy now
Do you know?
Asking 3 Right Questions minimizes the
RISK of Stock Investing
To Know
Right Stock | Right Price | Right Allocation
Find best stocks to buy now

Top Pharma Companies FAQs Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA ROE
Sanofi India Ltd. (S) Very Good 8,542 19,263 35.06 17.77 22.48 51.69
Abbott India Ltd. (M) Very Good 26,525 56,171 46.76 15.19 31.76 31.69
Laurus Labs Ltd. (S) Very Good 442.8 23,582 146.9 5.74 32.28 21.71
Dr. Reddys Laboratories Ltd. (L) Very Good 5,820 97,962 17.56 3.47 11.09 20.88
Torrent Pharmaceuticals Ltd. (L) Very Good 2,707 89,710 60.05 12.55 28.81 20.23

Based on the past year's gain, the best performing stocks are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) Yearly gain (%)
Lupin Ltd. (M) Somewhat Good 1,659 74,702 110.3
Zydus Lifesciences Ltd. (L) Very Good 1,008 1,00,367 95.47
Ipca Laboratories Ltd. (M) Very Good 1,291 32,375 85.90
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,831 28,149 83.51
Aurobindo Pharma Ltd. (M) Very Good 1,160 67,881 80.68
View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Sales Growth (%)
Laurus Labs Ltd. (S) Very Good 442.8 23,582 146.9 5.74 32.28 24.05
Granules India Ltd. (S) Somewhat Good 401.4 9,601 22.03 3.19 12.92 19.01
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,831 28,149 55.61 10.01 32.86 18.11
Gland Pharma Ltd. (M) Very Good 1,781 29,205 36.45 3.37 20.77 17.42
Mankind Pharma Ltd. (L) Very Good 2,092 87,765 53.18 9.58 36.72 15.71

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Profit Growth (%)
Laurus Labs Ltd. (S) Very Good 442.8 23,582 146.9 5.74 32.28 38.61
Dr. Reddys Laboratories Ltd. (L) Very Good 5,820 97,962 17.56 3.47 11.09 36.08
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,831 28,149 55.61 10.01 32.86 31.92
Biocon Ltd. (M) Somewhat Good 305.9 37,405 19.52 3.44 100.6 31.80
Granules India Ltd. (S) Somewhat Good 401.4 9,601 22.03 3.19 12.92 31.51
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
SEBI Registered: Investment Adviser - INA000013323
Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.
Compliance Officer:
Name: Shrikant Jagtap
Email : shrikant.jagtap@moneyworks4me.com
Mobile No: +91 97638 00745
Grievance officer:
Name: Mukta Vaze
Email : mukta.vaze@moneyworks4me.com
Mobile No:+91 98609 19463
Principal Officer:
Name: Atharva Bhide
Email : atharva.bhide@moneyworks4me.com
Mobile No:+91 91758 99463
Sitemap play-store Download APP play-store Download APP
linkedin facebook twitter youtube insta telegram
Address: MoneyWorks4Me Investment Advisers, B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Complaints: Register a Complaint | Complaint status | Cancellation and Refund Policy | PML Act | Grievance Redressal Process | Investor charter | Terms & Conditions | Disclaimer | Disclosure
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.